{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-138737","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.612400+00:00","generated_at":"2026-05-19T13:34:42.399914+00:00","sec_items":["1.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cabaletta Bio reports strong rese-cel efficacy data in myositis, SLE, and scleroderma at EULAR 2025","bullets":["7 of 8 myositis patients achieved clinical response off all immunomodulators; all 4 ASyS/DM patients achieved meaningful TIS response.","All 7 SLE patients achieved clinical response off immunomodulators and glucocorticoids; all non-renal SLE patients achieved DORIS.","Both scleroderma patients showed meaningful mRSS improvements after discontinuing all immunomodulators and steroids, sustained to 6 months.","In 18 patients with ≥4 weeks follow-up, 94% had no or Grade 1 CRS; 89% had no ICANS; enrollment accelerated to 51 patients actively enrolled.","Company terminated ATM program with TD Cowen; prior sales of ~2.6M shares for $7.9M gross proceeds; $192M unused capacity cancelled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-138737","json":"https://secwatch.observer/filing/0001193125-25-138737.json","markdown":"https://secwatch.observer/filing/0001193125-25-138737.md","text":"https://secwatch.observer/filing/0001193125-25-138737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/0001193125-25-138737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525138737/d78097d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T13:34:42.399914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}